CCM
IMUC

Compton Capital Management’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Compton Capital Management’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-250
Closed -$11K – 144
2014
Q2 		$11K Hold
250
– – 0.01% 141
2014
Q1 		$12K Buy
+250
New +$12.2K 0.01% 143

Other funds holding IMUC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Compton Capital Management's IMUC Position: Q3 2014 in Review

Compton Capital Management sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q3 2014, closing a stake of 250 shares — an estimated $11K sold.

Compton Capital Management first reported a position in IMUC in Q1 2014 and held it in 2 quarters. The position peaked at $12K in Q1 2014. 39 funds tracked by Wall St. Rank hold IMUC as of Q3 2014.

  • Compton Capital Management reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q3 2014 after selling out during the quarter.
  • Compton Capital Management sold 250 ImmunoCellular Therapeutics, Ltd. shares in Q3 2014, an estimated $11K.
  • Compton Capital Management first reported a position in ImmunoCellular Therapeutics, Ltd. in Q1 2014 and held it in 2 quarters.
  • Compton Capital Management's ImmunoCellular Therapeutics, Ltd. position peaked at $12K in Q1 2014.
  • 39 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q3 2014.

Based on Compton Capital Management's 13F filing for Q3 2014, filed 13 Nov 2014.